Nordic Nanovector: Funding, Investors & Team (Sep 2026)
Nordic Nanovector is a biopharmaceutical company dedicated to extending and improving the lives of patients with haematological cancers through the development and commercialisation of innovative targeted therapeutics. The company's lead clinical-stage product is Betalutin®, the first in a new class of antibody radionuclide conjugates (ARCs), designed to improve upon and complement current options for the treatment of non-Hodgkin lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities. Betalutin® is a tumour-seeking anti-CD37 antibody conjugated to a low-intensity radionuclide (lutetium-177). It is showing promising efficacy and tolerability in a Phase 1/2 clinical study in a difficult-to-treat NHL patient population. The company aims to develop Betalutin® for the treatment of patients with relapsed/refractory NHL. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. Nordic Nanovector is committed to building a pipeline of novel ARCs and antibody drug conjugates (ADCs) addressing multiple selected haematological malignancies based on proprietary technologies and expertise, and with technologies from partners where complementary.
Nordic Nanovector has raised $100k across 1 funding round on record, the most recent a Post-IPO Equity of $100k announced in Mar 2022.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Nordic Nanovector Company Profile and Key Stats
Latest funding round on record: Mar 2022.
Nordic Nanovector Funding Rounds
Nordic Nanovector Founders and Leadership Team
Contact details for the Nordic Nanovector team: 1 of 1 has an email address on file.
Start 14-day free trial →Nordic Nanovector Funding Compared to Other Biotechnology Startups
Nordic Nanovector's latest round of $100k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Nordic Nanovector in Biotechnology and Oslo
Companies Similar to Nordic Nanovector
Zelluna Immunotherapy AS is a privately owned Norwegian biopharmaceutical company founded in 2016 focused on…
Hofseth BioCare's key goal is to offer high benefit added biomarine elements for human applications. Through…
Circio Holding ASA is a company in the clinical stage that is developing immune activators for challenging…
IDEX, a biometrics software and fingerprint authentication company based in Oslo, Norway, was established in…
Arctic Bioscience is a biotechnology research company that develops products, solutions, and technologies…
Lytix Biopharma AS is a privately-owned pharmaceutical company focussed on anti-microbials and cancer…
Actithera is a company specializing in developing radioligand therapies through the application of medicinal…
NoMy is a company focused on creating sustainable and scalable solutions for alternative proteins by…
Oncoinvent AS designs and develops cancer treatments by applying known physical and chemical principles of…
Biosergen AS develops variants of nystatin with improved properties. Its pipeline products include S44HP, an…
NEXT offers secure and user-friendly fingerprint sensor technology for verification purposes in various…
We are a speciality pharmaceutical business committed to the creation and marketing of goods for people who…
Nordic Nanovector Funding FAQs
What does Nordic Nanovector do?
Nordic Nanovector is a biopharmaceutical company dedicated to extending and improving the lives of patients with haematological cancers through the development and commercialisation of innovative targeted therapeutics. The company's lead clinical-stage product is Betalutin®, the first in a new class of antibody radionuclide conjugates (ARCs), designed to improve upon and complement current options for the treatment of non-Hodgkin lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities. Betalutin® is a tumour-seeking anti-CD37 antibody conjugated to a low-intensity radionuclide (lutetium-177). It is showing promising efficacy and tolerability in a Phase 1/2 clinical study in a difficult-to-treat NHL patient population. The company aims to develop Betalutin® for the treatment of patients with relapsed/refractory NHL. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. Nordic Nanovector is committed to building a pipeline of novel ARCs and antibody drug conjugates (ADCs) addressing multiple selected haematological malignancies based on proprietary technologies and expertise, and with technologies from partners where complementary.
How much funding has Nordic Nanovector raised?
Nordic Nanovector has raised $100k across 1 round on record. The most recent is a Post-IPO Equity of $100k announced in Mar 2022.
When did Nordic Nanovector last raise funding?
Nordic Nanovector's most recent funding round on record is a Post-IPO Equity of $100k, announced in Mar 2022.
Who is the CEO of Nordic Nanovector?
Erik Skullerud is listed as CEO at Nordic Nanovector.
Where is Nordic Nanovector headquartered?
Nordic Nanovector is based in Oslo, Norway.
How many employees does Nordic Nanovector have?
Nordic Nanovector is in the 11-50 employee band.
How does Nordic Nanovector's funding compare to other Biotechnology startups?
Nordic Nanovector's latest round of $100k is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Nordic Nanovector Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Nordic Nanovector is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.